United States

AMAG Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Medicon Valley Inhalation Symposium

Participation Not Confirmed

Update your events

AMAG Pharmaceuticals and Norgine B.V. Ink Exclusive Licensing Agreement to Commercialize Ciraparantag in Europe, Australia and New Zealand

Lead Product(s): Ciraparantag

Therapeutic Area: Hematology Product Name: PER977

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Norgine

Deal Size: $290.0 million Upfront Cash: $30.0 million

Deal Type: Licensing Agreement July 23, 2020

Details:

Ciraparantag is in development for use in patients treated with direct oral anticoagulants and low molecular weight heparin when reversal of the anticoagulant effect of these products is needed for emergency surgery or due to life-threatening or uncontrolled bleeding.

AMAG Pharmaceuticals

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

Medicon Valley Inhalation Symposium

Participation Not Confirmed

Update your events

AMAG Announces Presentation of Ciraparantag Data at the International Society on Thrombosis and Haemostasis

Lead Product(s): Ciraparantag

Therapeutic Area: Hematology Product Name: PER977

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 12, 2020

Details:

Results from both studies, which randomized a total of 113 subjects, showed that steady-state anticoagulation induced by apixaban or rivaroxaban was reversed by a single IV infusion of ciraparantag in a dose-related manner as assessed by whole blood clotting time (WBCT).